INTRODUCTION
============

G protein-coupled receptors (GPCRs) represent the largest family of cell surface molecules involved in signal transduction. More than 1000 receptors for sensory (e.g., odor and light) and chemical stimuli (e.g., catecholamines, amino acids, peptides, and ions) have been identified based on their common structural and biochemical properties ([@b74-bt-25-012]). Because GPCRs represent 1--5% of the total cell surface proteins in mammals, it is not surprising that nearly 30% of United States Food and Drug Administration (FDA)-approved drugs target GPCRs ([@b84-bt-25-012]).

Historically, GPCRs were assumed to exist in equilibrium between active and inactive states, and thus activation of GPCRs would equally affect all downstream signaling pathways. However, accumulating evidences indicate that GPCRs exist in multiple conformational states where each conformation confers different downstream effects. In this context, some ligands are able to induce a differential receptor conformation which activates a different subset of signaling events, causing bias receptor signaling ([@b61-bt-25-012]). Biased GPCR signaling has been mainly studied on adrenergic and angiotensin receptors, but accumulating evidences indicate that this phenomenon may be extended to a wide variety of GPCRs currently targeted by pharmacological agents. This notion further complicates drug discovery efforts, but also holds the promise to design specific biased ligands that antagonize detrimental signaling pathways while stimulating beneficial downstream processes. Here, we seek to summarize the current knowledge of biased signaling on GPCRs and to discuss how identified biased ligands of selected receptors modulate disease outcomes.

ACTIVATION OF GPCRs
===================

GPCRs are often referred to as seven-transmembrane receptors (7TMRs) because their structures are characterized by the presence of seven α-helices crossing the plasma membrane. GPCRs are consisted of intracellular and extracellular loops. The NH~2~ terminus is exposed to the extracellular environment and the COOH terminus is located in the intracellular part. The intracellular domains and loops mediate the interaction between the receptor and intracellular signaling partners such as G proteins ([@b39-bt-25-012]; [@b46-bt-25-012]). The binding of exogenous ligands alters the conformation of critical domains of the seven-transmembrane helix pocket, which in turn causes the conformation changes of intracellular domains of the receptor. These changes promote the association of the receptor with a variety of heterotrimeric G proteins. They are composed of an α-subunit interacting with a βγ complex. Activation of the receptor promotes the exchange of a molecule of GDP by a molecule of GTP within the active site of the α-subunit. The binding of GTP to α-subunit causes the dissociation of the heterotrimeric complex, and both the GTP-bound α-subunit and the released βγ complex are then able to interact with intracellular or membrane effectors (e.g., enzymes or ion channels). The intrinsic GTPase activity of the α-subunit hydrolyses GTP into GDP, restoring its initial inactive conformation and its affinity for the βγ complex \[for detailed reviews, see ([@b131-bt-25-012]; [@b8-bt-25-012]; [@b39-bt-25-012]; [@b46-bt-25-012])\]. Up to now, at least 23 α-subunits derived from 17 different genes have been identified and are classified into four families (Gα~i/o~, Gα~s~, Gα~q/11~, and Gα~12~). At least 6 different β-subunits and 12 γ-subunits have been also discovered ([@b38-bt-25-012]; [@b126-bt-25-012]). Upon dissociation from the heterotrimeric complex, the various Gα subunits interact with the well-studied and classical effector enzymes in a highly specific manner. For instance, Gα~s~ activates (and Gα~i~ inhibits) adenylyl cyclase (AC), Gα~t~ activates photoreceptor cGMP phosphodiesterase (PDE), and Gα~q~ activates phospholipase C (PLC)-β ([@b115-bt-25-012]; [@b45-bt-25-012]). On the other hand, various Gβ subunits can activate or deactivate AC, activate PLCs or phosphatidylinositol 3-kinase (PI3K). Gγ subunits can activate various kinases including protein kinase D (PKD) ([@b72-bt-25-012]; [@b126-bt-25-012]) ([Fig. 1](#f1-bt-25-012){ref-type="fig"}).

In addition to signaling through G proteins, GPCRs can also activate G protein-independent signaling pathways mainly through multi-functional adaptor proteins called arrestins. The arrestins are a small family of proteins originally discovered in the visual system. Arrestins, which include arrestin-1 and -4 (expressed in retinal rods and cones) and ubiquitously expressed arrestin-2 (β-arrestin1) and arrestin-3 (β-arrestin2), were initially characterized for their roles in GPCR desensitization (uncoupling of the G protein from the cognate receptor) ([@b114-bt-25-012]; [@b59-bt-25-012]). Homologous desensitization is initiated by stimulation of the receptor with high concentrations of its agonist, resulting in a change in the receptor conformation to its active state. G protein-coupled receptor kinases (GRKs) can then phosphorylate the specific serine/threonine residues at C-terminus or intracellular loops of the activated receptor, which increases the affinity of β-arrestin for the receptor, thus resulting in the uncoupling of the Gα subunit from the receptor. By interacting with components of the endocytic machinery such as clathrin and the adaptor protein 2 (AP2) complex, β-arrestins also target the GPCRs for clathrin-mediated endocytosis and internalization ([@b58-bt-25-012]; [@b34-bt-25-012]). In addition to receptor endocytosis, β-arrestins were found to play prominent roles in signaling, trafficking, and ubiquitination of receptors ([@b111-bt-25-012]). It has been shown that internalized receptor-β-arrestin complexes can form a scaffold for mitogen-activated protein kinases (MAPKs) including ERK1/2, p38 and c-Jun N terminal kinase-3 (JNK3) to generate signalosomes, which may mediate long-lasting cell signaling in the cytosol ([@b63-bt-25-012]; [@b65-bt-25-012]; [@b40-bt-25-012]; [@b117-bt-25-012]). β-Arrestins have been also reported to scaffold AKT, PI3K and PDE4 in the context of various specific receptors both *in vitro* and *in vivo* \[reviewed in ([@b27-bt-25-012])\]. Lastly, β-arrestin1 has been recently proposed to mediate nuclear signaling such as microRNA (miR) processing after activation of β~1~-adrenergic receptors (β~1~-ARs) by biased ligands \[([@b55-bt-25-012]), see chapter 3.1\]. The examples of G protein- and β-arrestin-mediated downstream signaling pathways on GPCRs are summarized in [Fig. 1](#f1-bt-25-012){ref-type="fig"} and [2](#f2-bt-25-012){ref-type="fig"}.

MOLECULAR BASIS OF BIASED GPCR SIGNALING
========================================

As our understanding on *in vivo* effects of GPCR-targeting drugs becomes more profound, it has become clear that therapeutic strategies often require the modulation of a single specific downstream signaling pathway (i.e. G protein- v.s. β-arrestin-mediated signaling) in a given cell type or tissue. Most drugs targeting GPCRs often lack the specificity in this regard, and as such produce undesirable side effects. In recent years, there have been significant efforts to develop ligands that preferentially activate one beneficial GPCR signaling pathway, not another detrimental pathway. These functionally selective biased ligands have demonstrated the potential to use as novel therapies and have opened new possibilities in GPCR drug discovery ([@b96-bt-25-012]).

Although the detailed molecular mechanism of biased signaling is not yet well understood, it has been reported that biased GPCR ligands induce a unique receptor conformation, activating a particular signaling pathway. It is understood that the GPCR conformation stabilized by a G protein-biased ligand is distinct from the conformation stabilized by a β-arrestin-biased ligand. For example, a fluorescence-based study on activation of the arginine-vasopressin type 2 receptor by biased and unbiased ligands provided an interesting experimental notion, suggesting that the transmembrane helix 6 (TM6) and third intracellular loop at the receptor are associated with selective G protein signaling, whereas the TM7 and helix 8 (H8) regions at the receptor are required for selective β-arrestin recruitment ([@b91-bt-25-012]).

Another recent study used site-specific fluorine-19 nuclear magnetic resonance (19F-NMR) labels in the β~2~-AR to unveil conformational changes of the receptor upon activation by biased and unbiased ligands. It was shown that unbiased ligand's binding to the receptor primarily shifts the equilibrium toward the G protein-specific active state of helix 6, while β-arrestin-biased ligands predominantly regulate the conformational states of helix 7 ([@b61-bt-25-012]). Also, [@b136-bt-25-012] showed that phosphorylation of the receptor itself does not necessarily lead to a switching of the receptor coupling to different G proteins as once proposed ([@b26-bt-25-012]). It was also shown that the biased ligand-mediated signaling depends on the specific interaction between the ligand and the β~2~-AR's tyrosine 308 residue positioned on transmembrane helix 7 ([@b136-bt-25-012]). Despite these advances in biased signaling field, further structural studies are needed to unravel how the interaction between GPCR and ligand translates into the receptor conformation for selective coupling to different G proteins and β-arrestins. Such progress would move us closer to structure-based design of drugs specific to a particular signaling pathway.

It is well appreciated that the G protein-independent effector on GPCRs, β-arrestin, is recruited upon phosphorylation of GPCRs by GRKs specifically on their C terminal and intracellular loops. An interesting "barcode" hypothesis suggests that different GRKs phosphorylate distinct sites on the C terminus and internal loops of the receptor, thereby establishing a "barcode" that would instruct or determine the conformation for different β-arrestin functions. This would in turn determine the differential roles of GRKs and β-arrestins ([@b13-bt-25-012]). A detailed mapping of the β~2~AR phosphorylation by GRKs supported this hypothesis by demonstrating that the β-arrestin-biased ligand carvedilol recruited different GRKs and induced a different phosphorylation pattern from that of a full agonist isoproterenol ([@b79-bt-25-012]). The experimental evidence also indicates that the biased ligands can stabilize both the receptor and β-arrestin in conformations that are distinct from those associated with unbiased ligands. For example, [@b113-bt-25-012] used an intramolecular bioluminescence resonance energy transfer (BRET)-based biosensor of β-arrestin2 and a combination of biased ligands and/or biased mutants of three different GPCRs to show that β-arrestin can adopt multiple "active" conformations. These findings suggest the possibility that multiple distinct β-arrestin conformations can form various complexes with different binding partners, and thereby engage in different downstream signaling pathways.

Another interesting phenomenon in biased signaling observed for multiple GPCRs *in vitro* is the ability of biased ligands to recruit different subtypes of β-arrestins within a single receptor. Such differential involvement of β-arrestins can determine ligands' downstream effects on receptor such as trafficking, ubiquitination, or signaling. For example, it is known that the recruitment of β-arrestin1 and 2 can mediate internalization of mu-opioid receptor (MOR). Interestingly, morphine, an agonist with the low rate of MOR internalization primarily recruits β-arrestin2, whereas another agonist DAMGO can recruit either β-arrestin1 or 2, which leads to the high level of receptor internalization. DAMGO was also shown to induce receptor ubiquitination in a β-arrestin1-dependent manner ([@b41-bt-25-012]). Similarly, in delta-opioid receptor (DOR), an agonist SNC80, which causes the high internalization of the receptor, was shown to preferentially recruit β-arrestin1 over β-arrestin2. In contrast, agonists ARM390 and JNJ20788560 preferentially engage with β-arrestin2, resulting in the low rate of receptor internalization ([@b89-bt-25-012]). Endogenous ligands for the C-C chemokine receptor 7 also showed differential internalizing properties. The ligand CCL19 with high-internalizing capacity preferentially recruits β-arrestin2 over 1, whereas CCL21 with low-internalizing capacity engages with neither ([@b14-bt-25-012]). In addition, binding of ATP induces the greater interaction between P2Y2 receptor and β-arrestin1, whereas UTP nonselectively recruits both β-arrestin1 and 2 ([@b47-bt-25-012]). These studies support a novel interesting notion that different ligands for the same receptor can form distinct receptor-arrestin complexes.

Altogether, recent advances on GPCR biased signaling field suggest that biased GPCR ligands may have an important therapeutic potential in various diseases including cardiovascular diseases, neurological diseases, and cancers. As summarized in the following chapter and [Table 1](#t1-bt-25-012){ref-type="table"}, we seek to provide recent scientific progress on identifying novel biased ligands on selected highly-profiled GPCRs.

BIASED SIGNALING ON SELECTED GPCRS
==================================

β-adrenergic receptors and their biased ligands
-----------------------------------------------

β-adrenergic receptors (β-ARs), prototypical members of GPCR superfamily, are known for their regulation of contractile function in the heart. The stimulation of cardiac β~1~-and β~2~-AR by catecholamines such as adrenaline and noradrenaline activates the canonical G~s~-AC-cAMP-PKA signaling cascade, which increases calcium mobilization across different cellular compartments and sensitizes contractile proteins to cytosolic calcium. The overall physiological effect of cardiac β-AR stimulation is an increase in heart contractility (inotropic effect) and heart rate (chronotropic effect) ([@b100-bt-25-012]). The major subtype, β~1~-AR couples to the Gα~s~ protein, whereas β~2~-AR is able to couple to both Gα~s~ and Gα~i~ proteins ([@b53-bt-25-012]; [@b139-bt-25-012]; [@b86-bt-25-012]). Physiologically, the inotropic response to catecholamine stimulation is mediated mainly by β~1~-AR because the β~2~-AR-Gα~s~-mediated AC-cAMP-PKA response is inhibited by the co-activated β~2~-AR-Gα~i~ signaling ([@b141-bt-25-012]). However, β~2~-AR can regulate the effect of β~1~-AR on excitation-contraction coupling by activating Gα~i~ signaling. It is also known that activation of the β~2~-AR-Gα~i~ signaling protects the cardiomyocytes from the pro-apoptotic stimuli of excessive β~1~-AR stimulation and activates a pro-survival PI3K-Akt signaling cascade ([@b19-bt-25-012]; [@b147-bt-25-012]). However, prolonged activation of Gα~i~ through a synthetic receptor construct has been shown to lead to a depressed cardiac function and eventually the development of dilated cardiomyopathy in mice ([@b64-bt-25-012]). Switching of β~2~-AR coupling from Gα~s~ to Gα~i~ was found to play an important role in ischemic preconditioning-induced cardioprotection in the mouse heart ([@b125-bt-25-012]). In addition, the enhanced β~2~-AR-Gα~i~ signaling contributes to the dysfunction of both β~1~-AR and β~2~-AR in the failing heart ([@b142-bt-25-012]; [@b140-bt-25-012]). In 2007, Noma *et al*. showed that β~1~-AR-mediated β-arrestin signaling confers cardioprotection independent on G protein-mediated second messenger signaling ([@b80-bt-25-012]), bringing up a concept of biased signaling. Here, we summarize recent advances on β-AR biased signaling and highlight some of biased ligands which are used in clinic for a therapy.

**Fenoterol:** Racemic fenoterol is unique among the β~2~-AR agonists because it has been identified as a biased β~2~-AR ligand selectively coupling β~2~-AR to Gα~s~ protein. In the study by [@b142-bt-25-012] dysfunction of β~2~-AR but not β~1~-AR in the model of failing spontaneous hypertensive rats was induced by enhanced Gα~i~ signaling. Disruption of Gα~i~ signaling by pertussin toxin restored the blunted β~2~-AR contractile response in the failing heart. Interestingly, β~2~-AR agonist fenoterol had similar beneficial effects, which were due to selective activation of β~2~-AR-Gα~s~ signaling ([@b142-bt-25-012]). Functional selectivity of fenoterol was shown to depend on the stoichiometry at its two chirality centers ([@b137-bt-25-012]). Based on these observations, at least two other fenoterol derivatives (S, R′)-4′-methoxy-fenoterol and (S, R′)-4′-methoxy-1-naphthyl-fenoterol have been identified to selectively activate only Gα~s~ signaling pathways on β~2~-AR. These biased β~2~-AR ligands are therapeutically used for bronchial asthma and chronic obstructive lung disease ([@b98-bt-25-012]). These studies suggest that identifying novel Gα~s~-biased β~2~-AR ligands, which display a better efficacy, may provide a new therapy with the sustained efficacy by switching off β-arrestin-dependent receptor desensitization and down-regulation.

**Carvedilol:** Carvedilol is a well-known neurohormonal antagonist with multiple activities efficiently used in patients with congestive heart failure, stable angina pectoris ([@b31-bt-25-012]), myocardial infarction ([@b29-bt-25-012]), and myocardial ischemia-reperfusion injury ([@b11-bt-25-012]). It blocks both the β~1~-and β~2~-AR, resulting in the improved myocardial function and attenuation (or reversal) of adverse myocardial remodeling in heart failure. It also reduces the peripheral vascular resistance via vasodilation caused by antagonism of α~1~-AR. In addition to these well-known properties, carvedilol has a number of ancillary activities including antioxidant, anti-inflammatory, and antiapoptotic actions ([@b83-bt-25-012]; [@b30-bt-25-012]; [@b69-bt-25-012]). Carvedilol was shown to confer a range of cardioprotective effects, which were hypothesized to stem from its antioxidant effects and/or from direct inhibition of proapoptotic pathways ([@b109-bt-25-012]).

More importantly, carvedilol has been identified as a biased ligand on β~1~-AR and β~2~-AR, which selectively stimulates GRK5/6-and β-arrestin-dependent cardioprotective signaling without activating G proteins ([@b135-bt-25-012]; [@b54-bt-25-012]). Our group also showed that after stimulation of β~1~-AR by carvedilol, β-arrestin1 promotes the processing of five miRs (miR-125a-5p, miR-125b-5p, miR-150, miR-199a-3p and miR-214) in murine hearts and human cells ([@b55-bt-25-012]). MiRs, a class of ∼22 nucleotide small noncoding RNAs governing post-transcriptional repression of target mRNAs, were found to play important roles in normal cardiac physiology including the control of myocyte growth, contractility, and maintenance of cardiac rhythm as well as the pathogenesis of various heart diseases \[reviewed in ([@b90-bt-25-012])\]. The hypothesis for the mechanism by which carvedilol promotes miR processing is that carvedilol-induced GRK5/6 phosphorylation of β~1~AR mediates the recruitment of β-arrestin1 to the ligand-occupied receptor, resulting in the translocation of β-arrestin1 to the nucleus where it interacts with a subset of primary miRs and components of the Drosha microprocessor complex. Formation of a nuclear complex of β-arrestin1 with the heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) and Drosha, which are crucial nuclear RNA-binding proteins involved in miR processing ([@b57-bt-25-012]; [@b42-bt-25-012]), leads to activation of RNA helicase-independent miR processing ([@b55-bt-25-012]). In the mouse hearts, 7-day carvedilol infusion induced the upregulation of miR-150, miR-214, miR-125b-5p and miR-199a-3p, which were shown to be cardioprotective in the mouse models of heart failure ([@b107-bt-25-012]; [@b5-bt-25-012]; [@b130-bt-25-012]; [@b121-bt-25-012]). Moreover, our group also showed that 7-day infusion of carvedilol induced a unique gene signature on multiple genes related to cardiac disease. Genes upregulated by carvedilol included those encoding proteins in the tight junctions, malaria and viral myocarditis pathway, while downregulated genes were those encoding proteins in the glycosaminoglycan biosynthesis and arrhythmogenic right ventricular cardiomyopathy ([@b122-bt-25-012]). These findings make us speculate that carvedilol-responsive miRs can regulate the expression of various detrimental genes to confer cardioprotection ([Fig. 2](#f2-bt-25-012){ref-type="fig"}). We postulate that β~1~AR-mediated β-arrestin1 biased signaling provides an additional mechanism for the clinical efficacy of this β-blocker ([Table 1](#t1-bt-25-012){ref-type="table"}).

**Insulin signaling:** Interestingly, a recent study suggests that insulin signaling can also mimic the effects of a biased β~2~AR ligand and selectively activate a Gα~i~-biased signaling pathway ([@b37-bt-25-012]). Insulin and adrenergic stimulation represent two divergent regulatory systems that interact with overlapping downstream signaling pathways in adipocytes, liver, and skeletal and cardiac muscle. Stimulation of insulin receptor (IR) as well as βARs increases the glucose uptake in cardiac and skeletal muscle cells ([@b76-bt-25-012]; [@b21-bt-25-012]). In the heart, IR and β~2~AR form a complex and the stimulation of both receptors shares common downstream signaling components including GRK2 ([@b22-bt-25-012]; [@b21-bt-25-012]), Gα~i~ ([@b118-bt-25-012]) and β-arrestin ([@b62-bt-25-012]). Stimulation with either insulin or adrenergic receptors antagonizes the ability of the other to activate glucose transport ([@b71-bt-25-012]) and to modulate myocyte survival ([@b95-bt-25-012]).

In both diabetes and heart failure, circulating insulin levels are chronically elevated, leading to persistent stimulation of IRs. Despite the insulin resistance of adipocytes and skeletal muscle cells, the heart retains its insulin sensitivity to activate IR signaling cascades in type 2 diabetes ([@b138-bt-25-012]; [@b25-bt-25-012]). Hyperactive insulin signaling was shown to significantly accelerate adverse left ventricular remodeling in pressure overload-induced hypertrophy in rodents ([@b112-bt-25-012]). In the animal model of ischemia/reperfusion, insulin inhibited β-AR action in the hearts ([@b143-bt-25-012]). It was shown that in the animal hearts, insulin could directly impair adrenergic signaling pathways for contractile function via an IR-β~2~AR signaling complex. Insulin stimulation promotes crosstalk with β~2~AR pathways via insulin receptor substrate (IRS) and GRK2-mediated phosphorylation of the β~2~AR, which selectively activates a Gα~i~-biased β~2~AR signaling cascade to inhibit cAMP/PKA activities. Consequently, this IR-β~2~AR cross-talk leads to impaired β-AR-induced contractile function in cardiomyocytes and perfused mouse hearts ([@b37-bt-25-012]). However, these findings still need to be confirmed in humans, as it is known that diabetes is one of the risk factors for heart failure ([@b77-bt-25-012]), and heart failure is an insulin-resistant state ([@b25-bt-25-012]). If the hyperinsulinemia can indeed inhibit β~1~AR signaling via Gα~i~-biased β~2~AR signaling in humans, it is possible that hyperinsulinemic subjects with type 2 diabetes and heart failure might have increased sensitivity to the cardio-depressive effects of nonselective or β~1~-blockade, which is the standard care for managing patients with heart failure ([@b37-bt-25-012]).

Biased ligands on angiotensin receptors
---------------------------------------

Angiotensin II (AngII) type I receptor (AT~1~R), a primary regulator of blood pressure, is a prototype GPCR in the study of biased agonism. Upon binding of its natural ligand AngII to the receptor, Gα~q~ proteins are activated, resulting in intracellular inositol triphosphate (IP3) production, calcium mobilization, protein kinase C (PKC) activation, which altogether mediate the physiological effects of AT~1~R such as vasoconstriction and fluid retention. Moreover, the conformational rearrangement of 7 transmembrane α helices of the receptor also leads to the recruitment of β-arrestins, which mediates G protein-independent signaling, leading to overall positive inotropic and cardioprotective effects ([@b49-bt-25-012]). Angiotensin receptor blockers (ARBs) are clinically used for their anti-hypertensive activity, and some ARBs also show variable efficacies toward the protection against organ damage in diabetic nephropathy, cardiac hypertrophy, arrhythmia, and renal failure ([@b12-bt-25-012]). Multiple studies suggest that such additional tissue-protective benefits of ARBs may be mediated by β-arrestin signaling ([@b56-bt-25-012]; [@b68-bt-25-012]), thus the development of biased ligands has resulted in a promising therapy.

**SII:** One of the first β-arrestin-biased ligands to be described was the peptide \[Sar~1~, Ile~4~, Ile~8~\]-Ang (SII). This peptide was reported to exert anti-apoptotic cytoprotective effects in rat vascular smooth muscle cells ([@b1-bt-25-012]) and induce positive inotropic and lusitropic effects in rat primary cardiomyocytes by stimulating endogenous AT~1~R-β-arrestin signaling ([@b92-bt-25-012]). SII was also able to activate MAPK signaling in perfused rodent hearts ([@b4-bt-25-012]).

**TRV120027:** Utilizing SII as a pharmacological probe *in vitro* and *ex vivo* was helpful in elucidating downstream AT~1~R-mediated β-arrestin signaling. However, due to its low-affinity for the receptor, it has been difficult to study SII's potential pharmacological benefit in *in vivo* models. To overcome this limitation, custom-synthetic peptides have been developed based on SII sequence. Among the identified ligands, TRV120027 (TRV027) exhibited an improved potency compared to AngII in stimulating β-arrestin signaling, but no detectable G protein activation. TRV027 was shown to stimulate β-arrestin recruitment with subsequent activation of several kinase pathways such as p42/44 mitogen-activated protein kinase, Src, and Akt-endothelial nitric-oxide synthase pathways. TRV027 was also shown to increase cardiomyocyte contractility *in vitro* and decrease mean arterial pressure in rats *in vivo*, similar as unbiased ARBs such as losartan. However, unlike the unbiased ARBs, which decrease cardiac performance, TRV027 increased cardiac performance and preserved cardiac stroke volume ([@b127-bt-25-012]). Moreover, in healthy and heart failure canines, TRV027 also reduced pulmonary capillary wedge pressure, systemic and renal vascular resistance while preserving renal functions ([@b9-bt-25-012]). Because of this unique pharmacological profile, TRV027 has already entered phase II clinical trial as a novel therapeutic agent for acute heart failure ([@b49-bt-25-012]) ([Table 1](#t1-bt-25-012){ref-type="table"}).

Biased signaling in apelin receptor
-----------------------------------

The apelin receptor (also known as APJ, APLNR, AGTRL1) is a class A GPCR discovered in 1993 based on its sequence similarity with the AT~1~R ([@b81-bt-25-012]). APJ is widely expressed in brain and peripheral organs including heart, lung, kidney, or placenta ([@b48-bt-25-012]; [@b88-bt-25-012]). Since its discovery, a number of physiological and pathophysiological roles for the receptor have been identified, including regulation of cardiovascular function, fluid homeostasis, and the adipoinsular axis \[reviewed in ([@b87-bt-25-012])\]. APJ does not bind AngII but its natural ligand, apelin is a potent inotropic and vasodilatory agent. Apelin induces coupling of APJ to Gα~i~ ([@b44-bt-25-012]) with additional evidence for the involvement of Gα~q~-coupled activation of PLC and PKC ([@b50-bt-25-012]). Interestingly, the apelin receptor in the heart may act as a mechanosensor for stretch in an apelin-independent/G protein-independent manner through recruitment of β-arrestin ([@b110-bt-25-012]).

Apelin receptor system represents an attractive target in pathologies such as pulmonary hypertension and heart failure ([@b20-bt-25-012]; [@b16-bt-25-012]), which encourages to the development of its synthetic ligands. However, the limitation in translation to clinic is that chronic administration of an agonist would likely cause receptor desensitization with subsequent β-arrestin-mediated downregulation and loss of therapeutic efficacy. Thus, the development of agonists biased toward G protein signaling is essential. MM07, a cyclic apelin peptide, was shown to preferentially activate G protein responses with the low potency toward β-arrestin and receptor internalization. In rats, systemic infusions of this peptide caused a dose-dependent increase in cardiac output greater than apelin. Moreover, MM07 was an effective vasodilator in human forearm without loss of effects on repeat dosing, providing proof-of-concept of a clinical potential for biased ligands ([@b10-bt-25-012]). Another APJ ligand, K17P was also reported to be G protein-biased and displayed the strong impairment of β-arrestin-dependent signaling. This molecule lacks the vasodilator capacity of its mother molecule, which is due to the deletion of single C-terminal phenylalanine ([@b15-bt-25-012]). This reflects the impact of the specific structure of the ligand in determining the signaling pathway activated in the receptor ([Table 1](#t1-bt-25-012){ref-type="table"}).

Biased signaling in histamine receptors
---------------------------------------

The human histamine H~4~ receptor (H~4~R) belongs to the GPCR family and is considered as an important receptor in immune and inflammatory processes ([@b60-bt-25-012]). H~4~R was originally thought to signal only through Gα~i~ proteins and recently shown to also recruit and signal via β-arrestin2. This discovery made by its antagonist JNJ7777120, which was identified as a biased ligand in a β-arrestin2 recruitment assay ([@b104-bt-25-012]). The therapeutic potential of JNJ7777120 has been successfully studied in the mouse model of chronic dermatitis, where it inhibited pruritus and skin inflammation when used in combination with H1R antagonist ([@b82-bt-25-012]). Based on its indolecarboxamide structure, various JNJ7777120 analogues have been recently developed with the similar biased affinity toward β-arrestin2 ([@b78-bt-25-012]). The potentially improved therapeutic efficacy of these substances is yet to be evaluated.

Currently, one of the most clinically relevant therapies for histamine receptors is achieved through the regulation of H~2~R, which is pathologically implicated in gastric acid-related diseases but widely expressed in most tissues. The H~2~R stimulation increases adenylate cyclase activity and induces cAMP accumulation. The most commonly used H~2~R blocker, famotidine was shown to act as an "inverse agonist" by diminishing G protein-mediated increase of cAMP. Interestingly, famotidine also mimicked the effect of histamine, and induced receptor desensitization and internalization along with increased ERK phosphorylation in gastric epithelial cells ([@b2-bt-25-012]) ([Table 1](#t1-bt-25-012){ref-type="table"}).

Biased signaling in dopamine receptors
--------------------------------------

Dopamine receptors are another well-studied family of GPCRs largely because dopamine neurotransmission is important in multiple neuropsychiatric disorders. Among the dopamine receptors, dopamine receptor D2 (D2R) is one of the most validated drug targets in neurology and psychiatry. However, most drugs targeting the D2R are problematic, either being less efficacious than desired or possessing adverse side effects due to the activation or blockade of a subset of downstream signaling pathways.

D2R couples Gα~i/o~ to negatively regulate cAMP-PKA pathways and modulate intracellular Ca^2+^ levels by acting on ion channels or by triggering the release of Ca^2+^ from intracellular stores. In addition, more recent discoveries showed that dopamine receptors exert their *in vivo* effects through β-arrestin2-mediated protein kinase B (Akt)-glycogen synthase kinase 3 (GSK3) signaling cascades ([@b7-bt-25-012]). In humans, the Akt1/GSK3β signaling pathways are implicated in schizophrenia as evidenced by the low levels of Akt1 protein and reduced phosphorylation of GSK3β in the brain and lymphocytes of schizophrenic patients ([@b33-bt-25-012]). As Akt and GSK3 responses are mediated through ligands that are biased for β-arrestin signaling ([@b7-bt-25-012]), this may represent a novel approach to develop drugs with fewer side effects, greater therapeutic selectivity, and enhanced efficacy for treating schizophrenia. Indeed, two newly synthetized β-arrestin-biased ligands for D2R, UNC9975 and UNC9994 have already shown some promise by displaying robust antipsychotic drug-like activities in wild-type mice, which were abolished in β-arrestin2 knockout mice ([@b17-bt-25-012]). These two biased ligands also reduced schizophrenia-like behaviors in phencyclidine-treated or NR1-knockdown hypoglutamatergic mice, where they increased performance in various neurobehavioral tests, and elicited a lower level of catalepsy than standard antipsychotic drug and D2R antagonist haloperidol ([@b85-bt-25-012]).

Interestingly, biased ligands with the opposing pharmacology for the D2R, that is, the stimulation of G protein signaling pathways without activation of β-arrestin recruitment have been recently identified. The first example is MLS1547, which was shown to robustly activate G proteins while antagonizing of β-arrestin recruitment to the D2R ([@b36-bt-25-012]). Identification of such functionally selective ligands should help to dissect the roles of both signaling arms of the D2R in physiology and pathology. Moreover, functionally selective G protein-biased ligands may also result in improved therapies for certain neuropsychiatric disorders such as Parkinson's disease, in which D2R stimulation is desired ([Table 1](#t1-bt-25-012){ref-type="table"}). Several recent advances on D1R-biased signaling are also summarized in [Table 1](#t1-bt-25-012){ref-type="table"}.

Biased signaling in opioid receptors
------------------------------------

Opioid receptors are GPCRs, which are widely studied due to their crucial roles in pain management, drug abuse/addiction, and mood disorders. There are three major subtypes of opioid receptors: δ-receptor (DOR), κ-receptor (KOR), and μ-receptor (MOR). Majority of opioids exert their analgesic activities primarily via activating MOR. Upon activation, MOR predominately couples to Gα~i/o~, which orchestrates downstream signaling cascades including those contributing to antinociception. On the other hand, activation of β-arrestins, especially β-arrestin2 induces receptor internalization and desensitization, diminishing G protein-mediated signaling. Recent studies have shown that some MOR agonists such as fentanyl and \[D-Ala^2^, N-MePhe^4^, Gly-ol\]-enkephalin (DAMGO) have the high efficacy to recruit β-arrestin, whereas other opioids such as morphine are biased toward G protein signaling ([@b66-bt-25-012]; [@b70-bt-25-012]). MOR-mediated β-arrestin activation has been associated with the adverse effects of opioids such as dependence, and gastrointestinal and respiratory dysfunction. Indeed, in the absence of β-arrestin2, morphine produced less tolerance, dependence, constipation, and respiratory suppressive side effects. Moreover, a significantly enhanced and prolonged analgesic effect of morphine was observed in loss-of-function of β-arrestin2 ([@b124-bt-25-012]). Therefore, the development of biased G protein ligands for MOR holds a greater therapeutic potential compared to an unbiased one. In fact, a G protein-biased MOR ligand TRV130 (made by Trevena Inc., King of Prussia, PA, USA) with little β-arrestin recruitment activity has recently been reported to show potent analgesic effects with reduced respiratory depression and constipation compared to morphine ([@b28-bt-25-012]). TRV130 was delivered intravenously and has successfully completed phase I trials for safety in healthy volunteers ([@b116-bt-25-012]). The first encouraging results from phase II trials were reported in a randomized and double-blinded study in patients experiencing moderate-to-severe post-operative pain after bunionectomy. The results showed that TRV130 rapidly produces profound analgesia with no serious adverse effects, suggesting that G protein-biased MOR activation is a promising target for novel analgesics ([@b128-bt-25-012]).

Interestingly, biased ligands that are selective agonists at one desired pathway could also act as biased competitive antagonists for the undesired pathway. In general, MOR ligands with low efficacy for G protein activation also have low efficacy for β-arrestin2 recruitment, and in fact partial agonists such as buprenorphine do not significantly recruit β-arrestin2 in cell models ([@b66-bt-25-012]). In clinic, partial MOR agonists with bias toward antagonism of the β-arrestin2 would be beneficial for the treatment of opioid-induced constipation, which often complicates an analgesic therapy in patients. The pursuit of highly selective and potent non-peptide MOR ligands has yielded several more promising compounds including NAP, which acts as a peripherally selective MOR partial agonist. Being a P-glycoprotein substrate, NAP has limited access to the central nervous system. Moreover, it has no apparent analgesic effect due to its low efficacy in activating G protein-mediated signaling with no apparent effect on β-arrestin2 recruitment. However, its therapeutic potential lies in its ability to antagonize MOR full agonist-induced intracellular calcium flux and β-arrestin2 recruitment ([@b145-bt-25-012]). NAP dose-dependently restored the morphine-impaired intestinal motility without precipitating significant withdrawal of symptoms and thus held great promise in the treatment of opioid-induced constipation ([@b144-bt-25-012]) ([Table 1](#t1-bt-25-012){ref-type="table"}). In addition to multiple GPCRs as aforementioned, we summarize recent advances on serotonin 5-HT~2B~ receptor-and arginine-vasopressin V2 receptor-mediated biased signaling and highlight some biased ligands in [Table 1](#t1-bt-25-012){ref-type="table"}.

Biased GPCR signaling in cancer
-------------------------------

In contrast to the successful implementation of GPCR biased signaling concept for clinical benefit in the cardiovascular, neurological, behavior fields, there have been no reports demonstrating the utility of GPCR biased signaling for the treatment of cancer. However, a few recent studies reported the scientific progress in the potential use of biased signaling on endothelin receptors in cancer treatment.

Endothelin-1 (ET-1) is a peptide belonging to a family of the most potent vasoconstrictors. In addition to this function in the circulation, it has been implicated in various physiological and pathological conditions such as development, cell proliferation, differentiation, cardiac function and cancer ([@b108-bt-25-012]; [@b102-bt-25-012]). ET-1 is a well-recognized growth factor that is present in plasma and is produced by stromal and tumor cells. The ET-1 receptors, endothelin type A receptor (ET~A~R) and endothelin type B receptor (ET~B~R) are members of the GPCR family. ET~B~R is coupled to Gα~q~ and Gα~i~, and expressed mainly in endothelial cells, while ET~A~R, which is coupled to Gα~q~, Gα~s~ and Gα~12/13~, is expressed in vascular smooth muscle cells and cardiomyocytes as well as solid tumors ([@b106-bt-25-012]; [@b133-bt-25-012]; [@b6-bt-25-012]). In ovarian cancer, ET~A~R/ET-1 axis has been shown to promote tumorigenesis by promoting anti-apoptosis, invasion, and neoangiogenesis ([@b119-bt-25-012]; [@b103-bt-25-012]). Indeed, ET~A~R overexpression is associated with poor survival in patients with ovarian carcinoma ([@b123-bt-25-012]). However, a recent clinical study demonstrated that specific ET~A~R antagonists are ineffective as auxiliary anti-cancer treatment ([@b23-bt-25-012]). This might be explained by signaling bias of ET~A~R, which mediates both oncogenic and tumor suppressive properties. The known oncogenic downstream effects of ET~A~R are mediated by Gα~q~-coupled or β-arrestin-dependent signaling pathways ([@b119-bt-25-012]; [@b101-bt-25-012]). It was shown that GRK5/6-mediated phosphorylation of the receptor leads to the recruitment and nuclear translocation of β-arrestin, which in turn functions as an epigenetic regulator of several angiogenic/metastatic genes including β-catenin, thus promoting cell invasion ([@b101-bt-25-012]; [@b123-bt-25-012]). On the other hand, ET~A~R-mediated Gα~s~ activation induces AC/cAMP/PKA signaling, which can confer tumor suppressive effects as reported in several carcinoma-derived cell lines ([@b120-bt-25-012]; [@b35-bt-25-012]; [@b123-bt-25-012]). Given that stimulation of the ET-1/ET~A~R axis can activate both tumor suppressive and oncogenic properties in cancer cells, ligands biased toward Gα~s~/cAMP/PKA signaling might represent a novel potential therapy of various malignancies. Unfortunately, such therapeutic agents are yet to be developed.

Other GPCRs, which are involved in the progression of cancer and have been suggested as potential targets for yet-to-be-identified biased ligands, are CXC chemokine receptor 4 (CXCR4) and protease activated receptor 2 (PAR2). The enhanced expression of CXCR4 and aberrant downstream signaling are implicated in several cancers, where it is involved in tumor growth, vascularization, and metastasis ([@b43-bt-25-012]; [@b105-bt-25-012]). Also, PAR2, a GPCR with distinct biased signaling, has emerged as one of the promising therapeutic targets to inhibit rapidly metastasizing breast cancer cells ([@b73-bt-25-012]). Therefore, the development of novel biased ligands for CXCR4 and PAR2 may open new opportunities for cancer treatment.

DISCOVERING BIASED SIGNALING ON GPCR
====================================

Over the past decade, there has been a surge in publications to describe the identification of biased ligands at a wide variety of GPCRs. Accordingly, quantifying ligand bias has been an active area of research. One way to quantify ligand bias is to plot β-arrestin activity against G protein activity. For biased ligands, there would be different levels of β-arrestin-and G protein-mediated efficacies. Such data can also be represented as a matrix that incorporates data from multiple assays, or ligand bias factors that compare β-arrestin activity against G protein activity in different assays ([@b94-bt-25-012]). The quantification of the relative levels of bias is important in the identification of lead compounds and in the optimization of drug screening for biased ligands. Despite this effort, there are still considerable gaps in our understanding of bias. The conventional high throughput screening methodology used in the pharmaceutical industry is inadequate for the needs of novel biased ligand discovery. The drug discovery and experimental studies of biased signaling mechanisms require the use of highly sensitive assays and a standardized methodology to quantify responses related to the signaling pathways. For example, assays and analyses must be configured to remove any apparent bias resulting from the biological assay system and thus correctly identify true ligand bias. In addition, at least one of the endpoints requires the accurate quantification of a poor response. Lastly, the analysis must be compatible for use with a large number of compounds, and the data must be presented to enable medicinal chemistry to derive the relationship between structure and activity ([@b134-bt-25-012]).

In the past years, most groups have relied on comparing the maximal effects (E~max~) and potencies (EC~50~) of ligands for different signaling pathways. However, they are prone to errors in the interpretation in the setting of receptor reserve. For example, these parameters failed to account for the differences in the receptor reserve and amplification of different assays ([@b94-bt-25-012]). In assays with significant amplification such as second-messenger assays (e.g., cAMP formation), both full and partial agonists can reach the same maximal response, whereas in assays with little amplification such as assays that monitor the recruitment of β-arrestin to a receptor by enzyme complementation ([@b32-bt-25-012]), partial agonists have significantly lower maximal responses than full agonists ([@b94-bt-25-012]). Therefore, a partial agonist that reaches the maximal effect in one assay and halfmaximal effect in another assay would be incorrectly identified as being biased compared with a full agonist, which reaches the maximal response in both assays. Also, the difference in potencies between the full agonist and partial agonist may be smaller in assays with less receptor reserve ([@b94-bt-25-012], [@b93-bt-25-012]). The current best practice in the identification and quantification of biased agonism is thus complex and an ongoing topic of debate.

The key requirements for measuring bias signaling are a common reference compound to overcome observational and systemic bias as well as a scale, which accounts for both potency and maximal response of ligands. They allow the relative activity of ligands to be compared across assays. The current 'gold standard' method is the operational model of agonism that allows for the systematically independent quantification of agonist activity via the relative transduction ratio coefficient Δlog (τ/K~A~). The term τ incorporates agonist efficacy, receptor density and coupling within the system. The dissociation constant (K~A~) is the reciprocal of the conditional affinity of the agonist in the functional system \[for detailed reviews, see ([@b52-bt-25-012])\]. The alternative to this method is to use the bias factor β~lig~, which is calculated by the ratios of the efficacy of agonists for a given signaling pathway in a cell. This method was first used to quantify ligand bias and to identify weak biased compounds in β~2~-AR and AT~1~R. This method differs from the previous one by assuming that a single estimate of KA for the receptor (obtained from biochemical binding studies) should be used to fit the data with the operational model \[for detailed reviews, see ([@b93-bt-25-012])\]. However, the model to use the bias factor has limitations such as a possible error in the calculation of bias if the affinity of the agonist is changed when different signaling proteins are coupled to the receptor ([@b52-bt-25-012]). Another method for quantifying agonist bias offers the comparison of ratio of the maximal response (E~max~) to the EC~50~ value for an agonist \[Δlog (E~max~/EC~50~)\]. The equation has been employed to identify new biased MOR ligands. In this method, the relative signaling bias was quantified for each compound by calculating the difference in activity between β-arrestin recruitment assays (e.g., fluorescent labeling of β-arrestins and GPCRs) and G protein activation assays (e.g., cAMP assay). In such quantification, 0 represented no bias and +1 or -1 represented 10-fold bias for one signaling pathway \[for detailed reviews, see ([@b134-bt-25-012])\]. These methods for the identification and quantification of bias across large compound numbers have been essential for biased drug discovery.

One of increasingly recognized techniques for identification of GPCR signaling bias is BRET, which is a sensitive and non-destructive method commonly used in live cells to investigate protein-protein interactions or changes. BRET is a naturally occurring phenomenon resulting from the nonradioactive transfer of energy between luminescent donor and fluorescent acceptor proteins. In the sea pansy *Renilla reniformis*, the luminescence resulting from the catalytic degradation of coelenterazine by luciferase (*R*luc, donor) is transferred to the green fluorescent protein (GFP, acceptor), which in turn emits fluorescence upon dimerization of the two proteins. The BRET response depends on the distance and the relative orientation of the donor and acceptor. In many studies, donor and acceptor are tagged individually on two proteins that potentially assemble in signaling complexes. In other cases, subtle changes in the protein conformation upon complex assembly or disassembly can be studied using modified proteins that are labeled with both BRET donor and acceptor moieties engineered into the same protein in an intramolecular setting. Because of its fast reaction kinetics, this method allows for the real time detection of complexes or conformational changes that may be transient ([@b3-bt-25-012]; [@b67-bt-25-012]). BRET has been successfully applied to study GPCR dimerization ([@b3-bt-25-012]), and more recently to study proximal interactions of GPCRs with different signaling effectors including G proteins and β-arrestins ([@b113-bt-25-012]; [@b70-bt-25-012]; [@b15-bt-25-012]). Recent new advances in BRET technology include the discovery of biosensors, which do not involve the labeling of receptor as either a BRET donor or acceptor, and allow the identification of biased signaling from unknown compounds for any GPCR of interest ([@b75-bt-25-012]).

In addition to BRET, fluorescence resonance energy transfer (FRET) proximity and conformation assays as well as signaling assays such as MAPK activation have been widely used for the discovery of biased ligands ([@b94-bt-25-012]).

CONCLUSIONS
===========

The drug discovery strategy targeting only the primary ligand binding sites of GPCRs is becoming more and more difficult. As our understanding on *in vivo* effects of GPCR-targeting drugs becomes more profound, therapeutic strategies have often required the modulation of only a part of downstream effector pathways of a GPCR in a specific cell or tissue. Biased ligands with functional selectivity in specific GPCRs thus represent a new generation of drugs with increased specificity and fewer adverse effects. Much has been speculated regarding the potential advantages of the pharmacological feature of biased signaling and there are several biased ligands entering clinical studies. However, many gaps still exist. For example, few large animal and human studies have been performed. To completely translate existing basic research outcomes into clinical therapeutic options, further collaborative research should be pursued. Moreover, it is important for physicians and pharmacists to be continuously informed about which currently used drugs belong to the category of biased GPCR ligands and in which cases their use is beneficial or should be avoided due to the known adverse/unwanted effects.
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![Examples of G protein- and β-arrestin-mediated downstream signaling pathways on GPCRs. Upon agonist binding to GPCRs, both G proteins (Gα~12~, Gα~q/11~, Gα~i/o~, Gα~s~, Gβ and Gγ subunits) and β-arrestin are activated to mediate a variety of distinct downstream signaling pathways. Stimulation of Gβ subunit can activate PI3Kγ and Gγ subunit can activate PKD. Gα~12~ can activate Rho kinase signaling pathways and Gα~q~ can induce the mobilization of calcium from intracellular stores through activation of PLC/IP3. Gα~o~ signaling activates MEK/ERK pathway to mediate cell cycle progression. Gα~s~ proteins promote AC-induced PKA activation. Phosphorylation of GPCRs by GRK results in the recruitment of β-arrestin, which in turn desensitizes G protein signaling, mediates receptor trafficking to endosomes, and activates β-arrestin-dependent signaling.](bt-25-012f1){#f1-bt-25-012}

![Carvedilol-mediated β-arrestin biased signaling on β~1~-adrenergic receptors in cardiomyocytes and hearts. Carvedilol selectively stimulates GRK5/6- and β-arrestin-dependent cardioprotective signaling without activating deleterious G protein signaling. Carvedilol-mediated GRK5/6 phosphorylation of β~1~-adrenergic receptors leads to β-arrestin1's translocation into nucleus where β-arrestin1 interacts with a subset of primary miRs and components of the Drosha microprocessor complex. This results in an increased level of a subset of miRs, which act as cardioprotective miRs by repressing pro-apoptotic genes in cardiomyocytes and hearts.](bt-25-012f2){#f2-bt-25-012}

###### 

Overview of biased ligands on selected GPCRs

  Receptor                      Biased ligand      Pathway                Therapeutic area         References
  ----------------------------- ------------------ ---------------------- ------------------------ -----------------------------------------------------
  Angiotensin I receptor        SII                β-arrestin             Cardiovascular & Renal   [@b1-bt-25-012]; [@b9-bt-25-012]; [@b127-bt-25-012]
  TRV120027                                                                                        
  Apelin receptor               MM07               Gα~i~                  Cardiovascular           [@b10-bt-25-012]
  Arginine-vasopressin          MCF14              Gα~s~                  Renal                    [@b51-bt-25-012]
    V2 receptor                 MCF18                                                              
  MCF57                                                                                            
  β~1~-adrenergic receptor      Carvedilol         β-arrestin             Cardiovascular           [@b54-bt-25-012], [@b55-bt-25-012]
  Alprenolol                                                                                       
  β~2~-adrenergic receptor      Fenoterol          Gα~s~                  Pulmonary                [@b137-bt-25-012]; [@b142-bt-25-012]
  Carvedilol                    β-arrestin         Cardiovascular         [@b135-bt-25-012]        
  Dopamine D1 receptor          SKF83959           Gα~q~                  Neurology & Behavior     [@b24-bt-25-012]; [@b97-bt-25-012]
  SKF38393                                                                                         
  SKF82957                                                                                         
  SKF75670                                                                                         
  Dopamine D2 receptor          UNC9975            β-arrestin2            Neurology & Behavior     [@b17-bt-25-012]; [@b85-bt-25-012]
  UNC9994                                                                                          
  MLS1547                       Gα~i/o~            Neurology & Behavior   [@b36-bt-25-012]         
  Histamine H~2~ receptor       Famotidine         Gα~s~                  Gastrointestinal         [@b2-bt-25-012]
  Histamine H~4~ receptor       JNJ7777120         β-arrestin2            Inflammatory             [@b104-bt-25-012]
  κ-Opioid receptor (KOR)       Isoquinoline 2.1   Gα~i/o~                Neurology & Behavior     [@b146-bt-25-012]
  6′-GNTI                                                                 [@b99-bt-25-012]         
  RB-64                                                                   [@b132-bt-25-012]        
  μ-Opioid receptor (MOR)       TRV130             Gα~i/o~                Neurology & Behavior     [@b18-bt-25-012]; [@b28-bt-25-012]
  NAP                           Gα~i/o~            Neurology & Behavior   [@b145-bt-25-012]        
  Serotonin 5-HT~2B~ receptor   Ergotamin          β-arrestin             Neurology & Behavior     [@b129-bt-25-012]
